Chinook Therapeutics Long-Term Debt | KDNY

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Chinook Therapeutics

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
34.5 M	39.6 M	38.7 M	114 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
39.6 M	114 K	28.2 M

Quarterly Long-Term Debt Chinook Therapeutics

2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
29.7 M	33.2 M	34.5 M	35.8 M	37.2 M	38.5 M	39.6 M	40.8 M	37.1 M	38 M	38.7 M	30.4 M	30.9 M	31.3 M	114 K	32.1 M	32.6 M	33 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
40.8 M	114 K	33 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	13.2 M	-	-	-	Russia
Aclaris Therapeutics ACRS	1.56 M	$ 5.64	5.92 %	$ 691 M	USA
Akebia Therapeutics AKBA	48.2 M	$ 0.99	4.33 %	$ 255 M	USA
Alector ALEC	9.32 M	$ 2.19	2.1 %	$ 226 M	USA
Aligos Therapeutics ALGS	122 K	$ 5.08	0.96 %	$ 50.2 M	USA
Alkermes plc ALKS	63.3 M	$ 45.83	0.22 %	$ 7.55 B	Irlanda
Allogene Therapeutics ALLO	75 M	$ 1.79	0.28 %	$ 395 M	USA
Alnylam Pharmaceuticals ALNY	1.01 B	$ 248.37	0.14 %	$ 32.5 B	USA
Altimmune ALT	34.3 M	$ 3.31	1.22 %	$ 292 M	USA
ALX Oncology Holdings ALXO	4.53 M	$ 1.93	0.52 %	$ 104 M	USA
Amgen AMGN	50 B	$ 380.17	0.75 %	$ 205 B	USA
Amphastar Pharmaceuticals AMPH	620 M	$ 23.96	0.74 %	$ 1.12 B	USA
Amarin Corporation plc AMRN	6.08 M	$ 14.02	1.59 %	$ 5.82 B	Irlanda
Amneal Pharmaceuticals AMRX	2.57 B	$ 17.23	1.29 %	$ 5.4 B	USA
AbbVie ABBV	64.5 B	$ 261.94	1.87 %	$ 463 B	USA
AnaptysBio ANAB	12 M	$ 54.77	1.67 %	$ 1.58 B	USA
Anika Therapeutics ANIK	24.2 M	$ 21.22	1.7 %	$ 304 M	USA
ANI Pharmaceuticals ANIP	292 M	$ 70.92	1.04 %	$ 1.42 B	USA
Aptevo Therapeutics APVO	3.76 M	$ 1.87	2.75 %	$ 590 K	USA
AbCellera Biologics ABCL	137 M	$ 11.04	1.38 %	$ 3.3 B	Canada
Aquestive Therapeutics AQST	45 M	$ 4.89	2.41 %	$ 523 M	USA
Arcturus Therapeutics Holdings ARCT	20.8 M	$ 15.23	3.39 %	$ 417 M	Israel
Ardelyx ARDX	203 M	$ 3.54	0.14 %	$ 853 M	USA
Armata Pharmaceuticals ARMP	154 M	$ 5.3	1.84 %	$ 192 M	USA
Arcutis Biotherapeutics ARQT	108 M	$ 24.35	1.95 %	$ 3.1 B	USA
Artelo Biosciences ARTL	29 K	$ 5.15	1.1 %	$ 974 K	USA
Arvinas ARVN	400 K	$ 8.44	0.41 %	$ 598 M	USA
Arrowhead Pharmaceuticals ARWR	104 M	$ 80.24	0.11 %	$ 10.7 B	USA
Assembly Biosciences ASMB	2.06 M	$ 28.86	0.64 %	$ 324 M	USA
Actinium Pharmaceuticals ATNM	972 K	$ 1.25	6.87 %	$ 39 M	USA
Atara Biotherapeutics ATRA	9.35 M	$ 9.49	1.17 %	$ 119 M	USA
Agenus AGEN	30.5 M	$ 7.12	2.59 %	$ 212 M	USA
Aurinia Pharmaceuticals AUPH	52.3 M	$ 16.3	1.26 %	$ 2.19 B	Canada
Autolus Therapeutics plc AUTL	66.8 M	$ 1.94	2.93 %	$ 516 M	Britain
Atea Pharmaceuticals AVIR	842 K	$ 5.34	0.47 %	$ 435 M	USA
Axon Enterprise AXON	1.73 B	$ 491.2	2.47 %	$ 38.4 B	USA
Axsome Therapeutics AXSM	118 M	$ 216.73	0.75 %	$ 10.8 B	USA
Aytu BioScience AYTU	10.9 M	$ 2.0	0.5 %	$ 12.6 M	USA
BridgeBio Pharma BBIO	2.01 B	$ 72.33	0.1 %	$ 13.9 B	USA
BioCryst Pharmaceuticals BCRX	315 M	$ 8.2	0.92 %	$ 1.72 B	USA
Bicycle Therapeutics plc BCYC	669 K	$ 3.87	0.13 %	$ 268 M	Britain
Black Diamond Therapeutics BDTX	15.1 M	$ 2.03	2.52 %	$ 115 M	USA
Beam Therapeutics BEAM	140 M	$ 24.35	1.5 %	$ 2.41 B	USA
Biogen BIIB	6.29 B	$ 217.62	0.22 %	$ 31.9 B	USA
BioLineRx Ltd. BLRX	977 K	$ 2.48	0.2 %	$ 6.11 B	Israel
BioMarin Pharmaceutical BMRN	436 K	$ 66.22	0.82 %	$ 12.7 B	USA
Bristol-Myers Squibb Company BMY	42.8 B	$ 64.03	0.61 %	$ 130 B	USA
Benitec Biopharma BNTC	495 K	$ 12.11	0.08 %	$ 498 M	USA
Burford Capital Limited BUR	2.13 B	$ 4.35	1.13 %	$ 953 M	Britain